Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus

BACKGROUND: Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor expected to improve the lipid profile as well as glycemic control. However, findings from large-scale prospective trials have not been obtained. METHODS: We performed a multicenter prospective trial in patients with type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiba, Yukari, Yamakawa, Tadashi, Tsuchiya, Hirohisa, Oba, Mari, Suzuki, Daisuke, Danno, Hirosuke, Takatsuka, Yoji, Shigematsu, Hiroshi, Kaneshiro, Mizuki, Terauchi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031245/
https://www.ncbi.nlm.nih.gov/pubmed/29977423
http://dx.doi.org/10.14740/jocmr3464w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031245/
https://www.ncbi.nlm.nih.gov/pubmed/29977423
http://dx.doi.org/10.14740/jocmr3464w

Ejemplares similares